In contrast, EGFR, CCND1, and HER2 were amplified in 3.5–6.7% of tumours, often >9 times the normal copy number and frequently amplified in small amplicons indicative of the selective amplification of these genes. This evidence concerns the gene ERBB2 and neoplasm.